OR WAIT 15 SECS
Novartis will develop AVEO’s AV-380, an investigational humanized antibody targeting growth differentiation factor 15.
Novartis will develop AVEO Oncology’s first-in-class humanized antibody targeting growth differentiation factor 15 (GDF15), a proinflammatory cytokine. According to a press release from AVEO, AVEO could stand to earn up to $326 million for the deal, which includes a $15-million upfront payment and milestone payments of up to $311 million.
The antibody will be developed and investigated for its efficacy in treating wasting syndrome (e.g., weight and muscle loss), which is typically associated with chronic diseases such as cancer, chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. The metabolic condition, commonly known as Cachexia, is also associated with the clinical manifestation of anemia, inflammation, and suppression of immune functions.
Novartis will retain rights to all products and derivative products through the partnership and will be responsible for the commercialization and manufacturing of the medication and associated products.